Page 387 - Read Online

Page 16 of 16 Verkoeijen et al. J Cancer Metastasis Treat 2019;5:51 I http://dx.doi.org/10.20517/2394-4722.2019.06

65. Woods AJ, Roberts MS, Choudhary J, Barry ST, Mazaki Y, et al. Paxillin associates with poly(A)-binding protein 1 at the dense
endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem 2002;277:6428-37.
66. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-
nuclear transport. Proc Natl Acad Sci U S A. 1996;93:15174-9.
67. Lewis JM, Schwartz MA. Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem 1998;273:14225-30.
68. Hervy M, Hoffman L, Beckerle MC. From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr Opin
Cell Biol 2006;18:524-32.
69. Sathe AR, Shivashankar GV, Sheetz MP. Nuclear transport of paxillin depends on focal adhesion dynamics and FAT domains. J Cell Sci
2016;129:1981-8.
70. Sen A, De Castro I, DeFranco DB, Deng FM, Melamed J, et al. Paxillin mediates extranuclear and intranuclear signaling in prostate
cancer proliferation. J Clin Invest 2012;122:2469-81.
71. Wang Y, Gilmore TD. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim Biophys Acta
2003;1593:115-20.
72. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24-37.
73. Kumar A, Singh UK, Kini SG, Garg V, Agrawal S, et al. JNK pathway signaling: a novel and smarter therapeutic targets for various
biological diseases. Future Med Chem 2015;7:2065-86.